Kyorin gets option to license Cyrano’s CYR-064 intranasal theophylline for the Japanese market

Kyorin Pharmaceutical is paying an undisclosed fee for the option to license Japanese development and marketing rights to Cyrano Therapeutics’ CYR intranasal theophylline for the treatment of loss of smell, the companies said.

A Phase 2 trial of the nasal spray in patients with post-viral hyposmia that was initiated in 2023 is still underway. According to the announcement, results from the Phase 2 trial are expected later this year. Cyrano also recently announced the initiation of a Phase 1 trial of CYR-064 in Parkinson’s disease patients.

The company describes itself as “a private, venture-backed clinical stage regenerative medicine company.” Investors include US / Japanese venture capital firm Remiges Ventures, which co-led a $9 million Series B financing in 2024 with Lumira and DeepWork Capital.

Read the Cyrano Therapeutics press release

Share

published on

December 9-December 11: DDL 2026, Edinburgh, Scotland

April 27-30: RDD Europe 2027, Antibes, France

May 30-June 2: ISAM Congress 2027, Dublin, Ireland

June 23: SMI London, London, UK